We are pleased to announce that Dr. Bradley Thompson, Chief Executive Officer of Oncolytics Biotech Inc., has agreed to serve on Qu’s Board of Directors, where he will be joining the current Chairman, Dr. Hal Gunn, and Directors, Dr. Julia Levy, Dr. Simon Sutcliffe and Mr. Robert Freeman. Qu Biologics is in the final stages of preparing their first clinical trial application to Health Canada for the treatment of moderate to severe Crohn’s disease.
Dr. Thompson’s Biography:
Dr. Thompson has held the positions of Chairman of the Board, President and Chief Executive Officer of Oncolytics Biotech Inc. since April 1999. He has provided leadership to various organizations within the biotechnology sector for more than 20 years. Prior to his role with Oncolytics, Dr. Thompson was the Chief Executive Officer of SYNSORB Biotech from 1994 to 1999. From 1983 to 1994, Dr. Thompson worked in a senior role at the Alberta Research Council. He is the current Chairman of BIOTECanada. He received his PhD from the University of Western Ontario in the Department of Microbiology and Immunology.
“In 2012 to-date, Qu Biologics’ has closed two significant financing rounds at increasing valuations and doubled its team, and we are now gearing up for our first clinical trial, in patients with Crohn’s disease with our lead candidate drug product, QBECO,” declared Hal Gunn, CEO. “As the company grows, Dr. Thompson’s knowledge and experience in drug development and leading and growing biotech companies in Canada makes him an ideal choice as a Qu Board team member.”
Welcome Brad! Thank you so much for joining our team of Directors